Aquestive Therapeutics Faces Legal Scrutiny Amid Earnings Miss and Insider Sales
Pomerantz Law Firm has issued a formal reminder to Aquestive Therapeutics (AQST) investors regarding an ongoing class action lawsuit following a period of financial underperformance. The litigation coincides with a recent quarterly earnings miss and notable insider selling, creating a challenging regulatory and legal environment for the biotech firm.
Key Takeaways
- Pomerantz Law Firm has issued a formal reminder to Aquestive Therapeutics (AQST) investors regarding an ongoing class action lawsuit following a period of financial underperformance.
- The litigation coincides with a recent quarterly earnings miss and notable insider selling, creating a challenging regulatory and legal environment for the biotech firm.
Mentioned
Key Intelligence
Key Facts
- 1Pomerantz Law Firm is seeking lead plaintiffs for a class action lawsuit against Aquestive Therapeutics (AQST).
- 2Aquestive reported a Q4 2025 EPS miss of $0.13 and a revenue miss of $0.28M on March 4, 2026.
- 3The company's COO sold 45,791 shares of stock on March 11, 2026, amid the legal and financial pressure.
- 4The lawsuit focuses on potential misleading statements regarding the company's business and product pipeline.
- 5Aquestive recently appointed Dr. Matthew Greenhawt as Chief Medical Officer to oversee its allergy programs, including Anaphylm.
Who's Affected
Analysis
Aquestive Therapeutics, a pharmaceutical company specializing in the development of oral film delivery technologies, is currently navigating a period of heightened legal and financial pressure. The Pomerantz Law Firm, a prominent name in securities litigation, has intensified its efforts to organize a class action lawsuit against the firm. This development is part of a broader legal sweep by Pomerantz, which simultaneously issued alerts for Trip.com Group and Driven Brands Holdings, signaling a robust period of litigation activity targeting companies across diverse sectors. For Aquestive, the legal challenge arrives at a critical juncture as the company attempts to transition its lead candidates toward commercialization.
The crux of the litigation typically involves allegations that the company made materially false or misleading statements regarding its business operations or the efficacy and regulatory path of its key products. In the biotech sector, such lawsuits often follow a "stock drop" event. For Aquestive, the catalyst appears to be a combination of recent financial results and executive activity. On March 4, 2026, the company reported fourth-quarter and full-year 2025 financial results that missed analyst expectations, with a GAAP EPS loss of $0.26—missing estimates by $0.13—and revenue of $13M, which fell short of projections. This financial miss was compounded by reports of insider selling, specifically a transaction by the Chief Operating Officer involving over 45,000 shares, which often serves as a red flag for securities litigators.
On March 4, 2026, the company reported fourth-quarter and full-year 2025 financial results that missed analyst expectations, with a GAAP EPS loss of $0.26—missing estimates by $0.13—and revenue of $13M, which fell short of projections.
Aquestive’s portfolio is centered on its proprietary PharmFilm technology, with its lead candidate Anaphylm (epinephrine sublingual film) being the primary driver of future valuation. Any perceived lack of transparency regarding the FDA’s feedback on this program or the timeline for its New Drug Application (NDA) often serves as the foundation for shareholder action. Historically, small-cap biotech firms like Aquestive have faced a volatile regulatory landscape where even minor delays in clinical data or regulatory feedback can wipe out significant market capitalization, subsequently inviting legal challenges from firms like Pomerantz and Robbins LLP.
What to Watch
The involvement of Pomerantz Law Firm is significant given their history of pursuing high-stakes corporate and securities class action litigation. Their pursuit suggests a belief that there is a recoverable loss based on specific disclosure failures related to the company's financial health or pipeline progress. This creates a "legal overhang" for AQST shares, which can distract management and complicate future capital-raising efforts. For a company like Aquestive, which requires steady capital to fund the commercial launch of Anaphylm and the continued development of Libervant, a pending class action can increase the cost of capital and deter institutional entry.
Looking ahead, the biotech industry is seeing an uptick in these "reminders" as law firms leverage automated monitoring of stock volatility and earnings misses to identify potential targets. Investors should monitor the lead plaintiff deadline, as the appointment of a lead plaintiff often dictates the pace and aggression of the discovery phase. Furthermore, Aquestive’s upcoming regulatory milestones will be viewed through a dual lens: as potential catalysts for stock recovery and as potential evidence in the ongoing litigation. If the company can deliver clean clinical data and clear regulatory wins for Anaphylm, the immediate sting of the lawsuit may fade, but the current environment remains a cautionary tale for stakeholders in the volatile pharmaceutical sector.
Cite This Page
"Aquestive Therapeutics Faces Legal Scrutiny Amid Earnings Miss and Insider Sales." Biotech Intelligence Brief, March 13, 2026. https://getbiobrief.com/story/aquestive-therapeutics-legal-scrutiny-class-action
How we covered this story
Every story in our biotech coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the biotech space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled biotech-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |